These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28800680)

  • 1. Pharmacological inhibition of focal segmental glomerulosclerosis-related, gain of function mutants of TRPC6 channels by semi-synthetic derivatives of larixol.
    Urban N; Neuser S; Hentschel A; Köhling S; Rademann J; Schaefer M
    Br J Pharmacol; 2017 Nov; 174(22):4099-4122. PubMed ID: 28800680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor.
    Urban N; Wang L; Kwiek S; Rademann J; Kuebler WM; Schaefer M
    Mol Pharmacol; 2016 Jan; 89(1):197-213. PubMed ID: 26500253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli.
    Ilatovskaya DV; Palygin O; Chubinskiy-Nadezhdin V; Negulyaev YA; Ma R; Birnbaumer L; Staruschenko A
    Kidney Int; 2014 Sep; 86(3):506-14. PubMed ID: 24646854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease.
    Krall P; Canales CP; Kairath P; Carmona-Mora P; Molina J; Carpio JD; Ruiz P; Mezzano SA; Li J; Wei C; Reiser J; Young JI; Walz K
    PLoS One; 2010 Sep; 5(9):e12859. PubMed ID: 20877463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Coiled-Coil Assembly to Ca
    Polat OK; Uno M; Maruyama T; Tran HN; Imamura K; Wong CF; Sakaguchi R; Ariyoshi M; Itsuki K; Ichikawa J; Morii T; Shirakawa M; Inoue R; Asanuma K; Reiser J; Tochio H; Mori Y; Mori MX
    J Am Soc Nephrol; 2019 Sep; 30(9):1587-1603. PubMed ID: 31266820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A (+)-Larixol Congener with High Affinity and Subtype Selectivity toward TRPC6.
    Häfner S; Burg F; Kannler M; Urban N; Mayer P; Dietrich A; Trauner D; Broichhagen J; Schaefer M
    ChemMedChem; 2018 May; 13(10):1028-1035. PubMed ID: 29522264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease.
    Kistler AD; Singh G; Altintas MM; Yu H; Fernandez IC; Gu C; Wilson C; Srivastava SK; Dietrich A; Walz K; Kerjaschki D; Ruiz P; Dryer S; Sever S; Dinda AK; Faul C; Reiser J
    J Biol Chem; 2013 Dec; 288(51):36598-609. PubMed ID: 24194522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2).
    Chiluiza D; Krishna S; Schumacher VA; Schlöndorff J
    J Biol Chem; 2013 Jun; 288(25):18407-20. PubMed ID: 23645677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.
    Verheijden KAT; Sonneveld R; Bakker-van Bebber M; Wetzels JFM; van der Vlag J; Nijenhuis T
    J Am Soc Nephrol; 2018 Aug; 29(8):2099-2109. PubMed ID: 29954830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.
    Schlöndorff J; Del Camino D; Carrasquillo R; Lacey V; Pollak MR
    Am J Physiol Cell Physiol; 2009 Mar; 296(3):C558-69. PubMed ID: 19129465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
    Kim EY; Roshanravan H; Dryer SE
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase C epsilon (PLCε) induced TRPC6 activation: a common but redundant mechanism in primary podocytes.
    Kalwa H; Storch U; Demleitner J; Fiedler S; Mayer T; Kannler M; Fahlbusch M; Barth H; Smrcka A; Hildebrandt F; Gudermann T; Dietrich A
    J Cell Physiol; 2015 Jun; 230(6):1389-99. PubMed ID: 25521631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease.
    Dryer SE; Roshanravan H; Kim EY
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1041-1066. PubMed ID: 30953689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trpc6 inactivation confers protection in a model of severe nephrosis in rats.
    Kim EY; Yazdizadeh Shotorbani P; Dryer SE
    J Mol Med (Berl); 2018 Jul; 96(7):631-644. PubMed ID: 29785489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoskeleton Rearrangements Modulate TRPC6 Channel Activity in Podocytes.
    Shalygin A; Shuyskiy LS; Bohovyk R; Palygin O; Staruschenko A; Kaznacheyeva E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRPC Channels in Proteinuric Kidney Diseases.
    Hall G; Wang L; Spurney RF
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function, focal segmental glomerulosclerosis Trpc6 mutation minimally affects susceptibility to renal injury in several mouse models.
    Brown BJ; Boekell KL; Stotter BR; Talbot BE; Schlondorff JS
    PLoS One; 2022; 17(8):e0272313. PubMed ID: 35913909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel gain-of-function mutation in transient receptor potential C6 that causes podocytes injury.
    Yu M; Hu J; Ju T; Wang R; Wang M; Gao C; Xia Z
    Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):284-288. PubMed ID: 38814201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel gain-of-function mutation of TRPC6 Q134P contributes to late onset focal segmental glomerulosclerosis in a Chinese pedigree.
    Liu Z; Zhang H; Zhao S; Zhang Q; Zhang R; Han Y; Shao L; Zhao X
    Nephrology (Carlton); 2021 Dec; 26(12):1018-1025. PubMed ID: 34387384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel TRPC6 mutation that causes childhood FSGS.
    Heeringa SF; Möller CC; Du J; Yue L; Hinkes B; Chernin G; Vlangos CN; Hoyer PF; Reiser J; Hildebrandt F
    PLoS One; 2009 Nov; 4(11):e7771. PubMed ID: 19936226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.